Viewing StudyNCT00097214

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-05 @ 11:39 AM
Last Modification Date: 2024-10-26 @ 9:11 AM
Study NCT ID: NCT00097214
Status: COMPLETED
Last Update Posted: 2010-04-09
First Post: 2004-11-18
Brief Title: Carboplatin Plus Cetuximab for Treatment of Stage IIIBIV Non-Small Cell Lung Cancer NSCLC
Sponsor: Eli Lilly and Company
Organization: Eli Lilly and Company
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Non-small Cell Lung Cancer
Keywords:
Name View
Stage IV non-small cell lung cancer View
NSCLC View
Non-small View
Lung View
IIIB View
IV View
Carboplatin View
Cetuximab View
Stage IIIB non-small cell lung cancer View